Neurological aspects of menopause - influence of initiating hormone replacement therapy. <br>II. Neuropathic disorders

Wiesław M. Kanadys

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2003
vol. 2

Send email

Copy url:

abstract:

Neurological aspects of menopause - influence of initiating hormone replacement therapy.
II. Neuropathic disorders

Wiesław M. Kanadys

(Prz Menopauz 2003, 4: 59–64)

Online publish date: 2003/08/27

View full text Get citation

Menopause as well as hormone replacement therapy (HRT) may influence the course of diseases, which arised from dysfunction or primary damage in the central nervous system. During menopause great changeability of migraine headache is observed, and exacerbated migraine is associated with intensity of climacteric vasomotor symptoms. HRT may exacerbate migraine, although most women tolerate this treatment well. Frequency and severity of tension-type headache did not change significantly during menopause and as an effect of HRT. In women with epilepsy varying effects of menopause, as well as HRT on seizure activity were noted. Sleep disturbance, especially insomnia, increases in postmenopausal women. Initiating HRT significantly improves subjective sleep quality, while it has only a slight effect on both objective sleep quality (psychometry) and sleep architecture (polysomnographic study).

keywords:

Neurological aspects of menopause - influence of initiating hormone replacement therapy. II. Neuropathic disorders

Wiesław M. Kanadys

menopause, hormonal replacement therapy, headache, epilepsy, sleep disturbance

Neurological aspects of menopause - influence of initiating hormone replacement therapy.
II. Neuropathic disorders